Business
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced it has signed a contract with Telix Pharmaceuticals Limited (Telix; ASX: TLX, NASDAQ: TLX), a precision oncology company, for the initial order of four Cyclone® KIUBE cyclotrons at standard IBA conditions1. The systems will be installed at select RLS Radiopharmacies
About this update from Telix Pharmaceuticals Limited
[{"type":"image","alt":"IBA SA","displaySize":"","headline":null,"caption":"IBA SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":85,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SsPPJL6gCnLwqIjSXOR6Wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTExMA--/https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694","width":85,"height":85}},"lazy":false},{"type":"text","content":"Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced it has signed a contract with Telix Pharmaceuticals Limited (Telix; ASX: TLX, NASDAQ: TLX), a precision oncology company, for the initial order of four Cyclone® KIUBE cyclotrons at standard IBA conditions1. The systems will be installed at select RLS Radiopharmacies (RLS) sites in the United States (U.S.).","length":541,"tagName":"p"},{"type":"text","content":"This investment supports Telix’s strategic expansion of its U.S. manufacturing footprint with the goal of strengthening supply chain resilience and to enable in-house production of critical therapeutic and diagnostic isotopes and radiopharmaceuticals for cancer care. The agreement also contributes to the growth of IBA RadioPharma Solutions, reinforcing its leading position in the market. By combining IBA’s cyclotron expertise with Telix’s distribution and production footprint, this collaboration strengthens the collective capacity to meet the rising demand for sophisticated PET imaging tracers and other integrated theranostic solutions.","length":644,"tagName":"p"},{"type":"text","content":"Telix selected the Cyclone® KIUBE 180 for its high-current capacity, industrial reliability, and capacity for future upgrades. Each cyclotron will be equipped with QUANTM® Irradiation System (QIS®), the latest irradiation system developed by ARTMS, a wholly-owned subsidiary of Telix Pharmaceuticals. Together, these technologies will enable cGMP-compliant production of critical radio-metals including Gallium-68 (68Ga), Zirconium-89 (89Zr), Technetium‐99m (99mTc) and Copper-64 (64Cu) initially. The integration of this advanced targetry hardware represents a key technical miles...